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Abstract
Increasing the effectiveness of siRNAs through chemical modification is an important task. Here we
describe altritol and hexitol modified oligonucleotides targeting the B-Raf oncogene that is critical
for the growth and survival of melanoma cells. Using assays for apoptosis, DNA synthesis, colony
formation and B-Raf protein and message levels, we demonstrate that certain hexitol modifications
can improve the effectiveness of B-Raf siRNAs and also increase duration of action. Altritol modified
siRNAs were similar to or slightly less effective than unmodified B-Raf siRNA. Modifications at
the 3′ or 5′ end of the sense strand, at the 3′ end of the antisense strand, or within either strand were
well tolerated. The basis for the increased effectiveness of the hexitol-modified siRNAs is not fully
understood but may be partly due to increased stability to nucleases.
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1. Introduction
There is currently substantial interest in the potential therapeutic utilization of RNA
interference (RNAi) (de Fougerolles et al., 2007). In order to therapeutically exploit RNAi in
humans it will be essential to develop siRNAs that are specific, potent, persistent in their action,
and suitable for effective in vivo delivery. Many of these issues can be addressed through
various chemical modification approaches. A variety of strategies for siRNA modification have
been pursued including alterations in the backbone chemistry, 2′-sugar modifications,
nucleobase modifications and others, as recently reviewed (Corey, 2007; De Paula et al.,
2007; Kurreck, 2003; Manoharan, 2004; Peek and Behlke, 2007). One approach that we have
extensively employed is to replace the pentose ring of RNA with six carbon moieties forming
altritol, cyclohexenyl, or hexitol nucleic acids (Allart et al., 1999; Froeyen et al., 2000). We
have recently demonstrated that atritol-modified siRNAs targeting the mRNA for MDR1 (a
drug resistance gene) had a stronger and more persistent effect than unmodified siRNAs; this
was particularly true in cases where altritol modifications were at the 3′ ends of the sense or
antisense strands (Fisher et al., 2007). Incorporation of cyclohexenyl moieties into selected
positions of MDR1 siRNA also increased activity, possibly due to an increase in nuclease
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The mechanism of targeted mRNA degradation by siRNA is complex and not yet fully
understood. It involves the formation of an RNA-induced silencing complex (RISC) that
contains the Argonaute 2 protein and that specifically cleaves mRNAs complementary to the
antisense (guide) strand of the siRNA (Valencia-Sanchez et al., 2006). When designing
modified siRNAs, some key parameters should be considered. Effective siRNA duplexes
display reduced thermodynamic stability at the 5′-end of the antisense siRNA relative to the
3′-end (Reynolds et al., 2004). RISC cleaves the target mRNA near the middle of the
complementary region ten nucleotides upstream of the nucleotide at the 5′-end of the guide
strand yielding 5′-phosphate and 3′-hydroxyl termini. Based on these observations,
modifications at the 5′-end of the antisense strand that increase 5′ thermodynamic stability, or
impede 5′-O-phosphorylation, as well as modifications in the middle of the duplex that interfere
with RNase cleavage, are likely to reduce siRNA activity. However, it has been demonstrated
that some modifications, such as 2′-OMe and 2′-F modified nucleoside residues, can be
incorporated at the cleavage site without interfering with nucleolytic activity (Czauderna et al.,
2003; De Paula et al., 2007).
In the present report we have extended our studies of chemically modified siRNAs to examine
hexitol and altritol modifications placed at the 3′ ends of the sense or antisense strands, at the
5′ end of sense strands, or adjacent to the site of endonucleolytic cleavage. We have designed
siRNAs that target the message for human B-Raf, a member of the Raf family of serine/
threonine kinases that are key elements in the Erk MAP Kinase (Extracellular Signal Regulated
Kinase, Mitogen Activated Protein Kinase) signalling pathway that is essential for mitogenesis
and survival. Activating B-Raf mutations occur in approximately 50% of human melanomas,
with the most common form being the V600E mutation (Davies et al., 2002; Schreck and Rapp,
2006). Melanoma cells are highly dependent on B-Raf activity for growth and survival as
demonstrated by increased apoptosis and reduced cell growth rates subsequent to treatment
with pharmacological inhibitors of Raf kinases, or by siRNA-mediated inhibition of B-Raf
(Boisvert-Adamo and Aplin, 2006; Karasarides et al., 2004), or specifically of B-Raf V600E.
In the current study we have utilized 20-mer hexitol or altritol modified siRNAs targeted to
sites spanning the coding sequences flanking amino acids 461 or 600. After transfection of the
various B-Raf targeted siRNAs into A375 human melanoma cells, we have evaluated effects
on apoptosis, DNA synthesis, colony forming ability and levels of B-Raf protein and message.
Our results indicate that hexitol and altritol modifications are well tolerated and that some
hexitol modifications lead to significant increases in activity of B-Raf directed siRNAs, as well
as to increased duration of action.
2. MATERIALS AND METHODS
2.1. Synthesis and characterization of oligonucleotides
Altritol and hexitol modified 20-mer oligonucleotides were synthesized using classical
phosphoramidite chemistry on solid supports as previously described (Allart et al., 1999;
Froeyen et al., 2000) and were confirmed by mass spectrometry. The unmodified siRNA
oligonucleotides and non-targeting siRNA oligonucleotide (cat# D0001210-01-20, 5′-
UAGCGACUAAACACAUCAAUU 3′) were made by Dharmacon.
2.2. Cell culture
A375 human melanoma cells were obtained from E. Sharpless (UNC) and were grown in
DMEM-H medium containing 10% FBS. The cell line was grown in a humidified atmosphere
of 95% air and 5% CO2 at 37°C.
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2.3. Treatment of cells with siRNA oligonucleotides
A375 cells were cultured as described above. Hybridization of the siRNA strands was done in
Dharmacon universal buffer by heating the solutions to 90°C in a Perkin Elmer PCR machine
for 1.5 min, then gradually cooling to 30°C for 30 min. Transfection of siRNA using
Dharmafect 1 (Dharmacon, Lafyette, CO) was done according to the manufacturer's standard
procedure. The oligonucleotides bound to Dharmafect 1 were mixed in 10% FBS/DMEM-H
and incubated with cells at 37°C for 72 h. Cells were either plated in 6 well or 12 well plates
depending on experiment. All experiments were done with siRNA sequences termed BRAF461
(antisense sequence 5′-AUGAUCCAGAUCCAAUUCUdTdT-3′) or BRAF600 (antisense
sequence 5′-AUCGAGAUUUCUCUGUAGC dTdT-3′); these sequences span the codons for
amino acids 461 or 600 of the B-Raf protein.
2.4. Apoptosis and DNA synthesis assays
Apoptosis was measured using an Annexin V staining kit (Trivigen, Gaithersberg, MD)
followed by flow cytometry, usually at 3 days post transfection. Briefly, cells were harvested
with typsin EDTA, suspended in complete medium and washed once. Cells (2.5 × 105) were
incubated in the presence of Annexin V (diluted 1/250) for 30′ and then processed by flow
cytometry. DNA synthesis was measured by a Cell Proliferation BrdU ELISA assay (Roche
Diagnostics, Mannheim, Germany). Briefly, 1.25 × 104 transfected cells were plated in 96 well
plates for 72 h. The BrdU ELISA was performed according to the manufacturer's standard
procedure. The ELISA was read at 405 nM on a Bio-Tek Elx800 microplate reader.
2.5. Cell growth assay
A375 cells were treated with Dharmafect 1 complexes of standard or chemically modified
siRNA oligos as described above. Cells were then washed with PBS, harvested with trypsin-
EDTA and resuspended in 1 ml of a complete medium. The final cell number was enumerated
by using an electronic particle counter (Particle Data, Elmhurst, IL).
2.6. Colony-Formation Assay
Seventy-two h after transfection, 100 A375 cells from each treatment group were replated in
6 well plates containing a mixture 1% low gelling temperature agarose (SeaKem, Rockland,
ME) and complete DMEM-H medium with 10% FBS. After 14 days, surviving colonies larger
than 25 cells were counted. Survival was expressed as total colonies per well.
2.7. Measurement of B-Raf expression by western blotting
A375 cells were transfected with various siRNAs for 3 days. Cells were lysed with modified
RIPA buffer and equal amounts of protein were resolved on 10% SDS-polyacrylamide gels
and blotted onto polyvinyl difluoride membranes (Millipore, Bedford, MA). BRAF was
detected using mouse monoclonal anti-B-Raf antibody (Santa Cruz Biotechnology, Santa Cruz,
CA) at a dilution of 1:1000 and tubulin was detected using mouse monoclonal anti-tubulin
antibody (Sigma) at a dilution of 1:1000 followed by peroxidase-conjugated goat anti-mouse
IgG antibody (Calbiochem, San Diego, CA) at a dilution of 1:5000. Signals were detected by
enhanced chemiluminescence (ECL kit, Amersham Biosciences Inc). Image analysis was
performed with Scion Imaging Software (Fredrick, MD).
2.8. RT-PCR
RNA was isolated at times indicated using TRI REAGENT (Molecular Research Inc,
Cincinnati, OH) as per manufacturer's instructions. cDNA was synthesized using SuperScript
II reverse transcriptase (Invitrogen, Carlsbad, CA) as per manufacturer's instructions. The B-
Raf signal was normalized using human actin as an internal control. Primers were purchased
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from the Oligonucleotide Synthesis Core Facility, University of North Carolina. B-Raf forward
and reverse primer sequences were 5′CGAATGAAAACACTTGGTAGACGG3′ and 5′
CCCTGTTGTTGATGTTTGAATAAGG respectively. Actin forward and reverse primers
were 5′GCTCGTCGTCGACAACGGCT3′ and 5′
CAAACATGATCTGGGTCATCTTCTC3′.
2.9. Nuclease stability of hexitol and altritol modified siRNAs
Standard B-Raf siRNA and modified siRNA's were exposed to 10% fetal bovine serum at 37°
C for various times and degradation was monitored by 3% agarose gel electrophoresis with
ethidium bromide staining.
3. Results
The altritol and hexitol modified oligonucleotides used in this study are described in Table 1
and the structures of the nucleotides are given in Fig 1A. As indicated, modifications in sense
and antisense strands were placed at various positions particularly at or near the 3′ end or in
the middle of the sequence near the presumed cleavage site; in some cases modifications were
placed at the 5′ end of the sense strand. No modifications of the 5′ end of the antisense strand
were used since previous work had shown them to be inactive (Fisher et al., 2007).
In order to rapidly screen the various chemically modified oligonucleotides for biological
activity, we adopted a convenient assay for the initiation of programmed cell death based on
the binding of FITC- tagged annexin V to the surface of apoptotic cells; the amount of binding
is then quantitated by flow cytometry (Steensma et al., 2003). This screening approach was
chosen because inhibition of B-Raf is known to trigger apoptosis in melanoma cells (Boisvert-
Adamo and Aplin, 2006; Karasarides et al., 2004). This simple initial screen can then be
followed by more detailed analysis of promising candidates. As illustrated in the flow
cytometry histograms of Fig 1B, non–targeted siRNA produced only a slight increase over
control in terms of the number of apoptotic cells. By contrast, both unmodified B-Raf siRNA,
and a B-Raf siRNA that was hexitol modified in both strands, produced significant increases
in apoptosis, with the modified material displaying greater activity than the unmodified
oligonucleotide. Using this assay we generated dose-response curves for the same pair of
unmodified or hexitol -modified siRNAs and one additional hexitol duplex. As seen in Fig 1C,
significant effects on annexin V binding were seen at 50nM siRNA; however the dose-response
curve rose progressively to 200nM oligonucleotides. At all doses the hexitol-modified duplexes
tested were more active than the unmodified B-Raf siRNA. Relatively high concentrations of
siRNAs were needed to attain robust effects in terms of cytotoxicity. We believe that this is
due to the fact that a very substantial reduction in B-Raf levels is required to fully inhibit
mitogenic signaling pathways (Boisvert-Adamo and Aplin, 2006; Karasarides et al., 2004).
The hexitol duplexes utilized in Figs 1B, C were chosen based on preliminary screening similar
to that more fully illustrated in Fig 2 below.
Based on the findings of Figs 1, we screened all of the hexitol- and altritol -modified
oligonucleotides in Table 1 using the annexin V assay and treating cells at a concentration of
200nM. The siRNA duplexes tested contained either one modified (hexitol or altritol) strand
hybridized to an unmodified strand, or were composed of two modified strands. Fig 2A
illustrates the results for modifications of a single strand and Fig 2B for the cases where both
strands were modified. As indicated, many of the hexitol modified siRNAs were as or more
active than the corresponding unmodified BRAF 461 or BRAF 600 siRNAs. In some cases the
modified duplexes were substantially more active. For example, several hexitol duplexes
targeting the B-Raf 600 site were approximately twice as effective in inducing apoptosis as the
unmodified BRAF600 (2495/2497, 2595/2498, 2496/2497, 2496/2498). This overall
observation was repeated in several independent experiments. Interestingly, these siRNAs had
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at least one hexitol modification near the presumed site for cleavage of the mRNA target. In
this assay the altritol modifications seemed somewhat less helpful than the hexitol
modifications, with most of the altritol duplexes showing effects similar or slightly less than
those of the unmodified BRAF600 or BRAF461 siRNAs. However, none of the modifications
abrogated siRNA activity and thus it is clear that altritol and hexitol modifications at various
sites are well tolerated. In addition to the siRNAs illustrated in Fig 2, we also screened several
oligomers (# 2681-2688) with a single modification at the 3′ end of the sense or antisense
strand, since this type of modification seemed promising in previous work on another gene
target (Fisher et al., 2007). However, none of the singly modified oligonucleotides were as
effective as some of the doubly or multiply modified compounds illustrated in Fig 2 (data not
shown).
Since it is unwise to depend on a single assay to evaluate cytotoxic effects on cells, we also
examined several other parameters. Fig 3A displays effects of several siRNAs on DNA
synthesis monitored using a BrdU incorporation assay; as indicated, the B-Raf targeted siRNAs
reduced BrdU incorporation while the control siRNAs did not. A doubly modified hexitol
siRNA displayed slightly greater activity than the corresponding unmodified version but the
result was not statistically significant in this case. In a soft agar colony formation assay (Fig
3B), the doubly modified 2495/2497 duplex produced a major reduction of cell viability,
significantly greater than that attained by the BRAF600 unmodified version. Thus several
assays indicate that B-Raf siRNAs (but not control siRNAs) caused reductions in cell viability
and that in most cases hexitol -modified siRNAs were somewhat more effective.
We have also evaluated effects of the B-Raf siRNAs at the biochemical level. As indicated in
Fig 4A, the B-Raf 600 siRNAs caused a substantial reduction in the amount of B-Raf protein
as detected by western blotting. Once again a hexitol modified duplex (2495/2497) had a greater
effect than the unmodified siRNA, although both produced a marked reduction in B-Raf protein
levels without affecting levels of a control protein (tubulin). Interestingly, significant ‘knock
down’ of B-Raf was attained with as little as 25nM siRNA; however, substantially higher
concentrations were needed to attain strong effects on apoptosis or reduction of colony
formation (see above). This indicates that the melanoma cells can still function with a reduced
level of B-Raf and that rather profound ‘knock down’ or pharmacological inhibition is needed
to attain therapeutic effects, in agreement with other studies (Boisvert-Adamo and Aplin,
2006;Karasarides et al., 2004). In Fig 4B we demonstrate that siRNAs targeting the B-Raf 461
site can also effectively reduce levels of B-Raf protein without affecting tubulin; however, in
this case little difference was noted between the hexitol modified (2489/2493) and unmodified
siRNAs. We have also examined effects at the mRNA level using semi-quantitative RT-PCR.
As seen in Fig 5, B-Raf 600 siRNAs caused a significant dose-dependent reduction in B-Raf
message without affecting levels of actin message.
An important issue concerns the duration of action of siRNAs. To address this we performed
a time-course analysis comparing effects of an hexitol modified duplex with that of unmodified
B-Raf siRNA. As seen in Fig 6, both modified and unmodified B-Raf 600 siRNAs produced
substantial reductions in B-Raf protein levels at 72h, with a somewhat greater effect for the
hexitol compound. However, between 96h and 120h the cells treated with the unmodified
siRNA almost completely regained their pre-exposure levels of B-Raf, while the cells treated
with the hexitol modified siRNA displayed much lower levels. Recovery of the cells treated
with hexitol modified B-Raf siRNA was not complete until 160h. Thus the hexitol modified
siRNA seemed to have a substantially increased duration of action as compared to unmodified
B-Raf siRNA.
The basis for the increased effectiveness and duration of action of the hexitol modified siRNA
is not clear. One contribution may come from increased nuclease stability. Thus, as shown in
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Fig 7, a hexitol modified duplex (2495/2497) displayed increased stability to serum nucleases
as compared to an unmodified siRNA of the same sequence. However, other, as yet to be
determined, aspects of the modified siRNAs may also contribute to their effectiveness.
4. Discussion
There is increasing interest in pharmacological manipulation of Raf kinases for cancer
therapeutics, with both conventional small molecule and siRNA approaches being actively
pursued (Gollob et al., 2006; Schreck and Rapp, 2006). Obviously it would be advantageous
to be able to produce very active siRNAs able to selectively target mutant B-Raf. In this report
we have demonstrated that some hexitol modifications can increase the efficacy of of B-Raf
siRNA by a factor of two or more. This report also represents the first time that the hexitol
modification has been used in an siRNA. We have employed a rapid annexin V-based screening
approach to identify modified siRNAs with a strong biological effect (apoptosis). While we
believe that much of the apoptotic effect is due to ‘knock down’ of the B-Raf target, we cannot
completely exclude other possibilities. Thus, it is well known that siRNAs can have off-target
effects due both to induction of interferon pathways (Schlee et al., 2006) and to miRNA effects
related to partial sequence matches (Birmingham et al., 2006). Thus some promising candidates
in the apoptosis assay were further studied using more direct biochemical assays such as
western blotting for B-Raf.
A variety of chemical modifications have been employed to improve the characteristics of
siRNA (De Paula et al., 2007; Manoharan, 2004). Phosphorothioate modifications of the
backbone at the ends of strands have proven useful for stabilization against nuclease
degradation. Incorporation of 2′- F residues is well tolerated and can increase hybridization,
while several 2′-O methyl modifications are also usually well tolerated although full
modification can lead to loss of activity. LNA modifications provide increased duplex stability,
but only a small number of positions can tolerate such modifications. Replacing the pentose
ring with a six-membered ring as in hexitol, altritol and cyclohexenyl oligonucleotides allows
formation of A-type duplexes with RNA targets (Fisher et al., 2007; Nauwelaerts et al.,
2007), a key point for siRNA effectiveness. We have previously shown that such modifications
are well tolerated at 3′ positions and at some interior positions, but not at the 5′ position of the
antisense strand (probably because of the inability of the modified 5′ moiety to be
phosphorylated by cellular kinases) (Fisher et al., 2007). In some cases altritol and
cyclohexenyl modifications demonstrated substantially improved efficacy over unmodified
siRNA, while in the current study hexitol modifications provided improved results. The basis
of these effects is not clear at present; in addition to nuclease stability, one possibility is that
the six-membered ring modification assists in efficient loading of the RISC complex, but this
remains to be determined.
In this study we have shown that hexitol and altritol modifications of B-Raf siRNAs are well
tolerated at 3′ sites of sense and antisense strands, as expected, but also at sites adjacent to the
position on the antisense strand where mRNA cleavage takes place (for example
2493,2518,2503,2498,2508). This suggests that the hexitol or altritol modifications can be used
relatively freely in siRNAs. While some modifications, particularly hexitols, provided
substantial improvements in effect over unmodified B-Raf siRNAs, this was not true of all of
the substitutions. Somewhat to our surprise, the altritol modifications were not particularly
beneficial in this system although they did not reduce activity to any great degree. This contrasts
with our previous study using altritol -modified siRNAs against another gene target (Fisher et
al., 2007) where improved effectiveness was noted. Thus chemical modification strategies with
these moieties may need to be carefully optimized for particular siRNA targets rather than
being universally applicable. An important finding in this study is the increased duration of
action of hexitol modified siRNA; this could have interesting ramifications for therapeutic use
Fisher et al. Page 6













of this type of oligonucleotide. In summary, since these six-membered ring entities provide
both good thermodynamic stability and partial protection against nuclease cleavage (Allart et
al., 1999; Froeyen et al., 2000) (Nauwelaerts et al., 2007), the hexitol and altritol chemistries
may prove to be a useful addition to strategies for improving siRNA effectiveness.
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Fig 1A. Structures of the modified HNA and ANA nucleotides as repeating units of an
oligonucleotide.
Fig 1B. FACS analysis after staining with Annexin-V to detect apoptotic cells. A375 cells were
treated for 3 days with Dharmafect 1 transfection agent alone (TA), 200 nM non-targeting (NT)
siRNA's, 200 nM conventional unmodified B-Raf siRNA (RAF600), or 200 nM duplexed
hexitol modified B-Raf siRNA (2495/2497). Apoptotic cells were estimated by FITC-annexin
V binding and flow cytometry. The abscissa represents the relative fluorescence, and the
ordinate the number of cells. A window of annexin V binding (R1) was set to exclude all but
∼3% of the TA control population. The number of apoptotic cells due to the other treatments
was then estimated as the percentage of cells in the R1 window.
Fig 1C. Dose–response curves for hexitol modified siRNAs. A375 cells were treated with
various concentrations of non-targeting (NT) siRNA's, conventional unmodified siRNA
(RAF600) or duplexed hexitol modified siRNAs (2495/2497, or 2496/2498) for 3 days at 37°
C in complete medium. Cells were monitored for Annexin V-FITC expression by flow
cytometry. Results are the means and standard errors of triplicate determinations.
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Fig 2A. Hexitol / altritol single modified siRNAs-annexin V assay. A375 cells were treated for
3 days with Dharmafect 1 alone (TA), non-targeting (NT) siRNA's, conventional unmodified
siRNA, or modified siRNA's, all at 200 nM, as indicated in the figure. Cells were harvested
and were monitored for Annexin V-FITC binding by flow cytometry as described in Fig 1.
Results are means and standard errors of triplicate determinations.
Fig 2B. Hexitol / altritol doubly modified siRNAs-annexinV assay. The same procedure was
used to test doubly modified siRNA duplexes, as indicated in the figure. Results are means and
standard errors of triplicate determinations.
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Fig 3A. Effects of siRNAs on DNA synthesis. A375 cells were plated in 96 well plates at 6.25
× 103 cells per plate The following day the A375 cells were transfected with Dharmafect 1
alone (TA), non-targeting (NT) siRNA's, conventional unmodified siRNA(RAF600), or
duplexed HNA modified siRNA (2495/2497), all at 200 nM. Following a 3 day transfection,
a BudR ELISA assay was performed according to the manufacturer's standard procedure.
Results are means and standard deviations taken from 24 determinations. The TA and NT
values differ from both the RAF 600 and 2495/2497 values (*) with a statistical significance
of P<0.0001 using the Student's t-test.
Fig 3B. Soft agar colony formation. A375 cells were transfected with Dharmafect 1 alone (TA),
non-targeting (NT) siRNA's, conventional unmodified siRNA, or duplexed HNA modified
siRNA for 3 days. Cells were then counted and were replated in soft agar. Colony formation
was determined 14 days later as described in Methods. Results are expressed as colonies (>25
cells) per 100 cells plated. Data represents means and standard deviations from 12
determinations. The TA and NT controls differ from both the RAF600 and 2495/2497 values
(*) with a statistical significance of p<0.0001 using the Student's t-test. The RAF 600 and
2495/2497 values are different (#) with a statistical significance of P<0.002.
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Fig 4. BRAF expression by western blotting
(A) A375 cells were treated with Dharmafect 1 alone (TA), non-targeting (NT) siRNA's,
conventional B-Raf 600 unmodified siRNA or hexitol modified 2495/2497 siRNA at the
indicted concentrations for 3 days. Cells were lysed with modified RIPA buffer and equal
amounts of protein were resolved on 10% SDS-polyacrylamide gels, transblotted, and probed
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using mouse monoclonal anti-B-Raf antibody. Tubulin was detected using mouse monoclonal
anti-tubulin antibody Signals were detected by enhanced chemiluminescence. (B) A similar
experiment was performed with unmodified or hexitol modified (2489/2493) B-Raf 461 siRNA
used at 200 nM.
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Fig 5. B-Raf mRNA levels by RT-PCR
A375 cells were treated with increasing concentrations of siRNA for 72 h and cellular mRNA
levels were analyzed by RT-PCR as described in methods. The bar graph represents the ratio
of BRaf/Actin signals as analyzed by Scion Analysis software. Results are typical of several
experiments.
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Fig 6. Persistence of effect of hexitol -siRNA
A375 cells were treated with 100 nM hexitol modified (2495/2497) or conventional B-Raf
siRNA or with a non-targeted siRNA as a control. Cells were recovered on days 3-7 after
siRNA treatment and monitored for B-Raf expression by western blot. In the bar graph B-Raf
expression was normalized to the corresponding tubulin expression using Scion Image
software; then the B-Raf expression level at 72h in cells treated with the non-targeted (NT)
siRNA was taken as 100% and results for subsequent days for B-Raf siRNA treated cells were
compared to that value. The result presented is typical of several individual experiments.
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Fig 7. Nuclease stability of hexitol modified siRNAs
BRAF siRNAs were exposed to 10% fetal bovine serum at 37°C for different times and
monitored by 3% agarose gel electrophoresis with ethidium bromide staining.
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